Supporting our findings, Yvona Ward's research demonstrated that the GTP‐binding proteins Gem, negative regulators of the Rho‐Rho kinase pathway, play essential roles in BRCA prognosis, immune infiltration and immunotherapy response [42], suggesting that GMIP may impact the tumour immune environment through similar mechanisms. The gene discussed is GEM; the disease is neoplasm.